LTK
MOLECULAR TARGETleukocyte receptor tyrosine kinase
LTK (leukocyte receptor tyrosine kinase) is targeted by 33 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting LTK
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gefitinib | 5.67 | 290 |
| 2 | erlotinib | 5.55 | 256 |
| 3 | alvocidib | 4.52 | 91 |
| 4 | foretinib | 4.34 | 76 |
| 5 | tozasertib | 4.33 | 75 |
| 6 | vandetanib | 4.30 | 73 |
| 7 | ruxolitinib | 4.23 | 68 |
| 8 | bosutinib | 4.08 | 58 |
| 9 | doramapimod | 4.06 | 57 |
| 10 | bi 2536 | 4.01 | 54 |
| 11 | midostaurin | 3.85 | 46 |
| 12 | brigatinib | 3.81 | 44 |
| 13 | pazopanib | 3.69 | 39 |
| 14 | nintedanib | 3.61 | 36 |
| 15 | canertinib | 3.53 | 33 |
| 16 | tae 684 | 3.43 | 30 |
| 17 | fedratinib | 3.40 | 29 |
| 18 | gilteritinib | 3.40 | 29 |
| 19 | linifanib | 3.33 | 27 |
| 20 | upadacitinib | 3.09 | 21 |
| 21 | lestaurtinib | 3.04 | 20 |
| 22 | defosbarasertib | 2.89 | 17 |
| 23 | r 406 | 2.83 | 16 |
| 24 | cediranib | 2.83 | 16 |
| 25 | hesperadin | 2.77 | 15 |
| 26 | kw 2449 | 2.64 | 13 |
| 27 | ast 487 | 2.56 | 12 |
| 28 | lorlatinib | 2.48 | 11 |
| 29 | bms 754807 | 2.30 | 9 |
| 30 | su 014813 | 2.20 | 8 |
| 31 | rebastinib | 2.20 | 8 |
| 32 | asp 3026 | 2.08 | 7 |
| 33 | Crizotinib | 0.69 | 1 |
About LTK as a Drug Target
LTK (leukocyte receptor tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 33 compounds with documented LTK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
LTK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.